Ann: Investor Update, page-31

whatever. How do you know I’ve not submitted a complete set of questions to the Chair of the board rather than hijack a conference call?
so on a serious note, if you think I’m spouting nonsense fine but what then are your considered opinions into the whole reimbursement piece in the context of any therapy - drug or device- (and not necessarily just this device) that has made it to market with the level of evidence obtained to date (and that’s no criticism of their trial, it’s simply a fact it’s phase 1)? or do you just happily believe everything you hear? Based on past experience consulting I just happen to think (know) reimbursement agencies aren’t pushovers.